Industry News

Grants Received for Tuberculosis, Iron Overload Therapy

Published in Blood Weekly, December 27th, 1999

MetaPhore Pharmaceuticals, Inc., St. Louis, Missouri, announced that it has received two Small Business Innovation and Research (SBIR) grants from the U.S. Department of Health and Human Services totaling $1,166,166 to fund research for the discovery and development of novel chelation and metal-based therapeutics.

MetaPhore received a Phase II SBIR grant of $1,066,166 for the discovery of novel iron chelators to treat iron overload diseases (e.g. hemochromatosis, sickle-cell anemia, and thalassemia). An additional Phase I SBIR grant of $100,000 is for the discovery of metal-based antibiotics for the treatment of tuberculosis.

MetaPhore plans to use...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1999-12-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry